CENTOCOR ACQUIRES MERCIA DIAGNOSTICS
CENTOCOR ACQUIRES MERCIA DIAGNOSTICS MALVERN, Pa., Feb. 4 /PRNewswire/ -- Centocor, Inc. (NASDAQ: CNTO)
today announced the acquisition of Mercia Diagnostics Limited of Guildford, Surrey, U.K.
Mercia, founded in 1984, develops, manufactures, and markets diagnostic products for infectious disease. "With this acquisition, our Centocor Diagnostics Division moves into the rapidly expanding field of infectious diseases, adding to its already well-established position in cancer diagnostics," said Hubert J.P. Schoemaker, chairman and chief executive officer of Centocor. During 1991, infectious disease products accounted for approximately 19 percent of the $8 billion worldwide in vitro diagnostics market. Over the next five years, this area is expected to grow at an average annual rate of nearly 20 percent, making it one of the fastest growing segments in the in vitro diagnostics field. In addition to new product opportunities, Mercia provides Centocor Diagnostics with a European manufacturing base and a strategic link with Centocor's pharmaceutical business, led by HA-1A, a human monoclonal antibody for the treatment of septic shock and gram negative bacterial infections of the bloodstream. "This move was a natural evolution for both companies," said David P.
Holveck, president of Centocor Diagnostics, a division of Centocor. "The combination of Mercia technology, market opportunity, and Centocor Diagnostics' worldwide distribution strength make this a formidable union."
Centocor, based in Malvern, develops, manufactures, and markets diagnostic and therapeutic products for human health care. Centocor's products are based on monoclonal antibody technology and are primarily intended for use in infectious, cardiovascular, and autoimmune diseases and cancer. /delval/ -0- 2/4/92 /CONTACT: Richard Koenig of Centocor, 215-651-6122/ (CNTO) CO: Centocor, Inc.; Mercia Diagnostics Limited ST: Pennsylvania IN: MTC SU: TNM
CC -- PH026 -- 6711 02/04/92 12:44 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Feb 4, 1992|
|Previous Article:||ADVANCED MAGNETICS ANNOUNCES FILING OF INVESTIGATIONAL NEW DRUG APPLICATION|
|Next Article:||WASHINGTON POST COMPANY REPORTS FOURTH QUARTER AND YEAR END RESULTS|